HCI2509 is a small molecule inhibitor of LSD1 that has shown in vitro anti-tumor efficacy in triple negative breast cancer, and single-agent in vivo efficacy in both Ewing sarcoma and castration-resistant prostate cancer [35–38]. This evidence concerns the gene KDM1A and neoplasm.